News & Updates
Filter by Specialty:
Sofosbuvir/velpatasvir effective, safe for paediatric HCV
The direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) was effective and safe for the treatment of chronic hepatitis C virus (HCV) infection in individuals aged 6–18 years, the PANDAA-PED study has shown.
Sofosbuvir/velpatasvir effective, safe for paediatric HCV
25 May 2023
2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains
Both the 2-dose and 3-dose vaccination schedules of the four-component meningococcal serogroup B vaccine (4CMenB) appear to provide protection against a panel epidemiologically relevant strains in adolescents and young adults, according to a phase III study presented at ESPID 2023.
2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains
25 May 2023
Higher vitamin D dose beneficial for paediatric obesity-related asthma
A 50,000-IU loading dose of oral vitamin D plus 8,000 IU daily is effective and safe for increasing serum 25(OH)D levels to ≥40 ng/mL in children and adolescents with asthma who were overweight or obese, as opposed to the standard of care (SoC) dose of 600 IU daily, according to findings from the VDORA1* trial.
Higher vitamin D dose beneficial for paediatric obesity-related asthma
23 May 2023
Dupilumab cuts exacerbations, improves lung function in paediatric asthma patients with high eosinophils
In the post hoc analysis of data from the phase III LIBERTY ASTHMA VOYAGE study, the monoclonal antibody dupilumab reduced exacerbations and improved lung function in children aged between 6 and 11 years with moderate-to-severe asthma and baseline blood eosinophil count of ≥500 cells/μL.
